The licence holder advancing clinical cancer candidate SRA737 (the Chk1 inhibitor), has reported its Second Quarter Results. Simultaneously, it updated on SRA737’s clinical development. In the monotherapy study Sierra had previously announced that it would focus on high grade serous ovarian cancer (HGSOC), supported by emerging data in the field that provides clinical validation for Chk1 inhibition in this indication. Due to the enrolment of approximately 65 genetically defined HGSOC pa
10 Aug 2018
Sierra Oncology Q2 results show further prioritisation of high grade serous ovarian cancer patients in clinical plan
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sierra Oncology Q2 results show further prioritisation of high grade serous ovarian cancer patients in clinical plan
Sareum Holdings plc (SAR:LON) | 10.8 0 0.0% | Mkt Cap: 7.71m
- Published:
10 Aug 2018 -
Author:
Derren Nathan -
Pages:
6
The licence holder advancing clinical cancer candidate SRA737 (the Chk1 inhibitor), has reported its Second Quarter Results. Simultaneously, it updated on SRA737’s clinical development. In the monotherapy study Sierra had previously announced that it would focus on high grade serous ovarian cancer (HGSOC), supported by emerging data in the field that provides clinical validation for Chk1 inhibition in this indication. Due to the enrolment of approximately 65 genetically defined HGSOC pa